Keyword Analysis & Research: heron therapeutics

Keyword Analysis


Keyword CPC PCC Volume Score Length of keyword
heron therapeutics1.540.321894118
heron1.260.85665375
therapeutics0.270.464103012

Keyword Research: People who searched heron therapeutics also searched

Keyword CPC PCC Volume Score
heron therapeutics0.950.1943682
heron therapeutics news1.670.122594
heron therapeutics stock0.361231826
heron therapeutics stock price1.020.7142546
heron therapeutics sale rumors0.3168536
heron therapeutics stocktwits1.710.3626253
heron therapeutics pipeline0.030.8810210
heron therapeutics yahoo finance1.410.1260837
heron therapeutics headquarters1.990.4677361
heron therapeutics buyout rumors0.030.888497
heron therapeutics stock news0.780.1781655
heron therapeutics inc0.09189231
heron therapeutics inc stock0.130.5782454
ny da sued by heron therapeutics0.380.8183664
blue heron integrative therapeutics1.570.2557043
heron therapeutics inc news0.890.88355
blue heron therapeutics0.690.4578968

Search Results related to heron therapeutics on Search Engine

  • Acute Care and Oncology Care Solutions | Heron Therapeutics

    herontx.com

    https://www.herontx.com/

    WEBApr 11, 2024 · At Heron, we are unwavering in our commitment to improve the lives of patients. We aim to advance the therapeutic standard of care for patients through a portfolio of best-in-class therapies that bring together our innovative science and technologies with well-known pharmacology to deliver medicines that matter.

    DA: 2 PA: 10 MOZ Rank: 86

  • Investor Resources - Heron Therapeutics

    herontx.com

    https://ir.herontx.com/

    WEBApr 10, 2024 · Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates. 02/28/2024. Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024.

    DA: 11 PA: 65 MOZ Rank: 15

  • Developing Best-in-Class Medicine. Improving lives | Heron Therapeutics

    herontx.com

    https://www.herontx.com/about/

    WEBFeb 28, 2024 · Improving lives | Heron Therapeutics. Our mission is to improve the lives of patients by developing novel, best-in-class treatments to address some of the most important unmet patient needs. We aim to develop patient-focused solutions by applying our innovative science and technologies with well-known pharmacology.

    DA: 37 PA: 95 MOZ Rank: 33

  • Heron Therapeutics Announces FDA Approval of ZYNRELEF® …

    yahoo.com

    https://finance.yahoo.com/news/heron-therapeutics-announces-fda-approval-010000561.html

    WEBSAN DIEGO, Jan. 23, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the U.S. Food and Drug Administration (the...

    DA: 17 PA: 28 MOZ Rank: 93

  • Heron Therapeutics Announces FDA Approval of ZYNRELEF® …

    herontx.com

    https://ir.herontx.com/news-releases/news-release-details/heron-therapeutics-announces-fda-approval-zynrelefr-indication

    WEBSAN DIEGO, Jan. 23, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the U.S. Food and Drug Administration (the "FDA") has approved its supplemental New Drug Application ("NDA") for ZYNRELEF ® (bupivacaine and meloxicam) extended-release solution to expand the ...

    DA: 70 PA: 8 MOZ Rank: 96

  • Rethinking Treatments for Oncology Care | Heron Therapeutics

    herontx.com

    https://www.herontx.com/patients/oncology/

    WEBFeb 28, 2024 · Rethinking Treatments for Oncology Care | Heron Therapeutics. At Heron, we’re focused on improving the standard of care—developing solutions that help patients and healthcare providers manage and reduce the side effects that sometimes go along with cancer treatments.

    DA: 33 PA: 97 MOZ Rank: 70

  • Heron Therapeutics Announces FDA Approval of a Significant …

    herontx.com

    https://ir.herontx.com/news-releases/news-release-details/heron-therapeutics-announces-fda-approval-significant-indication

    WEBDec 9, 2021 · Heron is continuing to study ZYNRELEF in additional procedures with plans to submit a second sNDA to the FDA in the second half of 2022 to support a broad indication for soft tissue and orthopedic surgical procedures, which is intended to cover the full 14 million target procedures.

    DA: 32 PA: 45 MOZ Rank: 4

  • Heron Therapeutics Announces FDA Approval of ZYNRELEF® …

    prnewswire.com

    https://www.prnewswire.com/news-releases/heron-therapeutics-announces-fda-approval-of-zynrelef-indication-expansion-to-include-additional-orthopedic-and-soft-tissue-procedures-302042620.html

    WEBSAN DIEGO, Jan. 23, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX ), a commercial-stage biotechnology company, today announced that the U.S. Food and Drug Administration (the...

    DA: 2 PA: 41 MOZ Rank: 81

  • Our Focus - Acute Care and Oncology Care | Heron Therapeutics

    herontx.com

    https://www.herontx.com/patients/

    WEBFeb 28, 2024 · Oncology Care. We’re focused on elevating the standard of care—developing solutions that help patients and enable oncologists to manage and reduce the negative side effects that commonly go along with cancer treatments. Read More. Sign-Up for Email Updates. Receive news and updates on Heron’s latest innovations.

    DA: 78 PA: 98 MOZ Rank: 82

  • Redefining Acute Care | Heron Therapeutics

    herontx.com

    https://www.herontx.com/patients/acute-care/

    WEBWith extensive experience in the acute care setting, we are focused on improving the standard of care to address the most critical public health needs, improve patient outcomes, reduce healthcare costs, and deliver medicines that make a difference.

    DA: 91 PA: 26 MOZ Rank: 91